Physician profile
Thorsten Leucker
NPI 1013206119
$53,418.98
in general payments reported to CMS, 2019-2025
9 companies · $8,985 in 2025
The $8,985 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $11K · 2021: $11K · 2022: $1,590 · 2024: $2,262 · 2025: $8,985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,151 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,016 · Food and Beverage: $80.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,150.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,016.00 |
| Food and Beverage | $80.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $39,070.71 | 2019-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $5,238.44 | 2020-2025 | |
| Novo Nordisk INC | $3,902.77 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $2,780.00 | 2021-2025 | |
| Esperion Therapeutics, INC. | $2,400.00 | 2020 | |
| Abiomed | $25.40 | 2025 | |
| Travere Therapeutics, INC. | $1.66 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thorsten Leucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.